JP2018510343A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510343A5 JP2018510343A5 JP2017549301A JP2017549301A JP2018510343A5 JP 2018510343 A5 JP2018510343 A5 JP 2018510343A5 JP 2017549301 A JP2017549301 A JP 2017549301A JP 2017549301 A JP2017549301 A JP 2017549301A JP 2018510343 A5 JP2018510343 A5 JP 2018510343A5
- Authority
- JP
- Japan
- Prior art keywords
- sample
- biomarkers
- biomarker
- subject
- biomarker panel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 claims description 134
- 238000000034 method Methods 0.000 claims description 53
- 208000024827 Alzheimer disease Diseases 0.000 claims description 17
- -1 peroxyredoxin-1 Proteins 0.000 claims description 17
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 16
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims description 16
- 239000012634 fragment Substances 0.000 claims description 13
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 12
- 230000006735 deficit Effects 0.000 claims description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 9
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 8
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 208000027626 Neurocognitive disease Diseases 0.000 claims description 6
- 102000001708 Protein Isoforms Human genes 0.000 claims description 6
- 108010029485 Protein Isoforms Proteins 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 210000005013 brain tissue Anatomy 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 238000004949 mass spectrometry Methods 0.000 claims description 5
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 5
- 210000003296 saliva Anatomy 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 210000002700 urine Anatomy 0.000 claims description 5
- 108010085238 Actins Proteins 0.000 claims description 4
- 102000007469 Actins Human genes 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 229940039856 aricept Drugs 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 229960003530 donepezil Drugs 0.000 claims description 4
- 229940108366 exelon Drugs 0.000 claims description 4
- 229960003980 galantamine Drugs 0.000 claims description 4
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 4
- 229960004640 memantine Drugs 0.000 claims description 4
- 229940033872 namenda Drugs 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 229940051845 razadyne Drugs 0.000 claims description 4
- 229960004136 rivastigmine Drugs 0.000 claims description 4
- 206010012289 Dementia Diseases 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 3
- 238000001502 gel electrophoresis Methods 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000013918 Apolipoproteins E Human genes 0.000 claims description 2
- 108010025628 Apolipoproteins E Proteins 0.000 claims description 2
- 102000007345 Chromogranins Human genes 0.000 claims description 2
- 108010007718 Chromogranins Proteins 0.000 claims description 2
- 108090000996 Cofilin 1 Proteins 0.000 claims description 2
- 102000004360 Cofilin 1 Human genes 0.000 claims description 2
- 102000000989 Complement System Proteins Human genes 0.000 claims description 2
- 108010069112 Complement System Proteins Proteins 0.000 claims description 2
- 102000019205 Dynactin Complex Human genes 0.000 claims description 2
- 108010012830 Dynactin Complex Proteins 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 102000004878 Gelsolin Human genes 0.000 claims description 2
- 108090001064 Gelsolin Proteins 0.000 claims description 2
- 229920002527 Glycogen Polymers 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 2
- 201000002832 Lewy body dementia Diseases 0.000 claims description 2
- 102100032514 MARCKS-related protein Human genes 0.000 claims description 2
- 101710136868 MARCKS-related protein Proteins 0.000 claims description 2
- 102100027869 Moesin Human genes 0.000 claims description 2
- 101710105361 Phosphoglucomutase 1 Proteins 0.000 claims description 2
- 102100030999 Phosphoglucomutase-1 Human genes 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- UGPMCIBIHRSCBV-XNBOLLIBSA-N Thymosin beta 4 Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(C)=O UGPMCIBIHRSCBV-XNBOLLIBSA-N 0.000 claims description 2
- 102100035000 Thymosin beta-4 Human genes 0.000 claims description 2
- 102000005918 Ubiquitin Thiolesterase Human genes 0.000 claims description 2
- 108010005656 Ubiquitin Thiolesterase Proteins 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 102000050760 Vitamin D-binding protein Human genes 0.000 claims description 2
- 101710179590 Vitamin D-binding protein Proteins 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 230000030741 antigen processing and presentation Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 230000015271 coagulation Effects 0.000 claims description 2
- 238000005345 coagulation Methods 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 210000004292 cytoskeleton Anatomy 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 108010036236 extracellular matrix receptor Proteins 0.000 claims description 2
- 210000001650 focal adhesion Anatomy 0.000 claims description 2
- 229940096919 glycogen Drugs 0.000 claims description 2
- 230000034659 glycolysis Effects 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 210000000274 microglia Anatomy 0.000 claims description 2
- 230000006724 microglial activation Effects 0.000 claims description 2
- 230000002025 microglial effect Effects 0.000 claims description 2
- 108010071525 moesin Proteins 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 238000004393 prognosis Methods 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 108010079996 thymosin beta(4) Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 description 5
- 210000001642 activated microglia Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950007874 solanezumab Drugs 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021102858A JP2021177180A (ja) | 2015-03-17 | 2021-06-22 | アルツハイマー病の診断及び治療のための材料及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1504432.4 | 2015-03-17 | ||
| GB201504432A GB201504432D0 (en) | 2015-03-17 | 2015-03-17 | Materials and methods for diagnosis and treatment of alzheimers disease |
| PCT/EP2016/055883 WO2016146783A1 (en) | 2015-03-17 | 2016-03-17 | Materials and methods for diagnosis and treatment of alzheimer's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021102858A Division JP2021177180A (ja) | 2015-03-17 | 2021-06-22 | アルツハイマー病の診断及び治療のための材料及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510343A JP2018510343A (ja) | 2018-04-12 |
| JP2018510343A5 true JP2018510343A5 (https=) | 2019-05-09 |
| JP6954839B2 JP6954839B2 (ja) | 2021-10-27 |
Family
ID=53016214
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549301A Active JP6954839B2 (ja) | 2015-03-17 | 2016-03-17 | アルツハイマー病の診断及び治療のための材料及び方法 |
| JP2021102858A Pending JP2021177180A (ja) | 2015-03-17 | 2021-06-22 | アルツハイマー病の診断及び治療のための材料及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021102858A Pending JP2021177180A (ja) | 2015-03-17 | 2021-06-22 | アルツハイマー病の診断及び治療のための材料及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10718785B2 (https=) |
| EP (1) | EP3271728B1 (https=) |
| JP (2) | JP6954839B2 (https=) |
| CA (1) | CA2979773A1 (https=) |
| GB (1) | GB201504432D0 (https=) |
| WO (1) | WO2016146783A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201509134D0 (en) * | 2015-05-28 | 2015-07-15 | Electrophoretics Ltd | Biomolecules involved in Alzheimer's disease |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR102034929B1 (ko) * | 2017-09-27 | 2019-10-22 | 한양대학교 산학협력단 | Nckap1 단백질 또는 상기 단백질을 암호화하는 유전자를 포함하는 신경계 퇴행성질환의 예방 또는 치료용 약학적 조성물 |
| EP3764102A4 (en) * | 2018-03-09 | 2021-12-15 | National University Corporation Tokyo Medical and Dental University | DETECTION OF ALZHEIMER'S DISEASE (MA), FRONTOTEMPORAL LOBAR DEGENERATION (FRONTOTEMPORAL LOBAR DEGENERATION), AMYOTROPHIC LATERAL SCLEROSIS (ALS), PARKINSON'S DISEASE (PD) AND INDICATED LEWY-BODY DEMENTIA (PARL) MARCKS PHOSPHORYLATION |
| KR102063610B1 (ko) * | 2018-05-23 | 2020-01-08 | 충북대학교 산학협력단 | 퇴행성 신경질환 진단용 신규한 바이오마커 및 이의 용도 |
| KR101992060B1 (ko) * | 2018-10-30 | 2019-06-21 | 아주대학교산학협력단 | 알츠하이머치매 진단 체액 바이오마커 후보 단백4종 |
| KR102232200B1 (ko) * | 2019-03-13 | 2021-03-25 | 아주대학교산학협력단 | 알츠하이머치매 진단 바이오마커 |
| US20220003787A1 (en) * | 2018-10-30 | 2022-01-06 | Ajou University Industry-Academic Cooperation Foundation | Biomarker proteins for diagnosing alzheimer's dementia and use thereof |
| CN109738653B (zh) * | 2019-01-11 | 2022-04-12 | 湖南诺琪生物科技有限公司 | 用于阿尔茨海默症的检测、诊断或风险预测的抗原蛋白组合以及包含其的试剂盒 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| CN110261272B (zh) * | 2019-07-05 | 2020-08-18 | 西南交通大学 | 基于地理探测和pca对pm2.5浓度分布的关键影响因子筛选方法 |
| CN112336859A (zh) * | 2019-08-06 | 2021-02-09 | 上海绿谷制药有限公司 | 通过抑制t细胞摄取氨基酸治疗阿尔茨海默病的方法 |
| EP4051812A1 (en) * | 2019-10-28 | 2022-09-07 | AgenT | Biomarkers and uses thereof for diagnosing the silent phase of alzheimer's disease |
| KR102313455B1 (ko) * | 2020-02-27 | 2021-10-15 | 이화여자대학교 산학협력단 | 알츠하이머병 경도인지장애의 진단 또는 알츠하이머병 치매로의 진행 위험성 예측 방법 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CN112695084A (zh) * | 2021-02-08 | 2021-04-23 | 山东大学第二医院 | 诊断阿尔茨海默病和阿尔茨海默病进展的生物标志物及应用 |
| GB202102399D0 (en) * | 2021-02-19 | 2021-04-07 | Univ Manchester | Methods of determining alzheimer's disease |
| WO2022192019A1 (en) * | 2021-03-08 | 2022-09-15 | The Children's Medical Center Corporation | Methods for diagnosis and treatment of alzheimer's disease |
| CA3226615A1 (en) * | 2021-07-23 | 2023-03-30 | Ian Pike | Blood-based diagnostic assays for alzheimer's disease |
| WO2023235871A2 (en) * | 2022-06-03 | 2023-12-07 | Seer, Inc. | Systems, compositions, and methods relating to neurodegenerative diseases |
| WO2024073067A2 (en) * | 2022-09-30 | 2024-04-04 | Mayo Foundation For Medical Education And Research | Assessing and treating tremor |
| CN121606708B (zh) * | 2026-02-03 | 2026-04-28 | 四川大学华西医院 | 一种用于治疗阿尔茨海默症的病理血脑屏障靶向纳米制剂及其制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO2004001865A1 (ja) | 2002-06-19 | 2003-12-31 | Kabushiki Kaisha Toshiba | 熱電素子とそれを用いた電子部品モジュールおよび携帯用電子機器 |
| WO2005020784A2 (en) | 2003-05-23 | 2005-03-10 | Mount Sinai School Of Medicine Of New York University | Surrogate cell gene expression signatures for evaluating the physical state of a subject |
| EP1658502A2 (en) * | 2003-08-20 | 2006-05-24 | Genova Ltd. | Secreted polypeptide species and use thereof |
| US7794948B2 (en) * | 2003-11-07 | 2010-09-14 | Vermilllion, Inc. | Biomarkers for alzheimer's disease |
| WO2006110621A2 (en) * | 2005-04-11 | 2006-10-19 | Cornell Research Foundation, Inc. | Multiplexed biomarkers for monitoring the alzheimer's disease state of a subject |
| US20120071337A1 (en) * | 2009-01-26 | 2012-03-22 | Electrophoretics Limited | Methods |
| US8865411B2 (en) | 2009-03-26 | 2014-10-21 | National Institutes Of Health (Nih) | Methods of identifying modulators of TDP-43 mediated cellular toxicity |
| WO2011005893A2 (en) * | 2009-07-07 | 2011-01-13 | Abbott Laboratories | Biomarkers and methods for detecting alzheimer's disease |
| EP2553466A4 (en) | 2010-04-01 | 2013-10-16 | Banyan Biomarkers Inc | MARKERS AND ASSAYS FOR DETECTING NEUROTOXICITY |
| GB2511221B (en) | 2011-12-09 | 2020-09-23 | Veracyte Inc | Methods and compositions for classification of samples |
| GB2511525A (en) * | 2013-03-05 | 2014-09-10 | Randox Teoranta | Methods and Compositions for the Diagnosis of Alzheimer's Disease |
| GB201310203D0 (en) * | 2013-06-07 | 2013-07-24 | Electrophoretics Ltd | Materials and methods relating to Alzheimer's disease |
| GB201322094D0 (en) * | 2013-12-13 | 2014-01-29 | Electrophoretics Ltd | Methods and compositions relating to alzheimers disease |
-
2015
- 2015-03-17 GB GB201504432A patent/GB201504432D0/en not_active Ceased
-
2016
- 2016-03-17 US US15/559,371 patent/US10718785B2/en active Active
- 2016-03-17 JP JP2017549301A patent/JP6954839B2/ja active Active
- 2016-03-17 EP EP16714282.7A patent/EP3271728B1/en active Active
- 2016-03-17 WO PCT/EP2016/055883 patent/WO2016146783A1/en not_active Ceased
- 2016-03-17 CA CA2979773A patent/CA2979773A1/en active Pending
-
2021
- 2021-06-22 JP JP2021102858A patent/JP2021177180A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510343A5 (https=) | ||
| US20180224463A1 (en) | Methods and means for diagnosing spondylarthritis using autoantibody markers | |
| JP2011521630A (ja) | ゲノミクスまたはプロテオミクス発現プロファイリングを用いて腎同種移植の拒絶反応を診断する方法 | |
| JP2011517939A (ja) | 急性心臓同種移植拒絶反応を診断する方法 | |
| US20220057409A1 (en) | Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair | |
| JP2026016513A (ja) | アルツハイマー病を判定するためのタンパク質マーカー | |
| Klafki et al. | Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40? | |
| Gal et al. | Detergent insoluble proteins and inclusion body-like structures immunoreactive for PRKDC/DNA-PK/DNA-PKcs, FTL, NNT, and AIFM1 in the amygdala of cognitively impaired elderly persons | |
| Virtanen et al. | Intrathecal human herpesvirus 6 antibodies in multiple sclerosis and other demyelinating diseases presenting as oligoclonal bands in cerebrospinal fluid | |
| JP6046053B2 (ja) | Ｂｃｌ−２様タンパク質１１のＳＲＭ／ＭＲＭアッセイ | |
| JP6141876B2 (ja) | インスリン受容体タンパク質に対するｓｒｍ／ｍｒｍアッセイ | |
| ES2975228T3 (es) | Derivados de GFAP para el diagnóstico de accidente cerebrovascular | |
| Clark et al. | Advances in blood-based protein biomarkers for Alzheimer's disease | |
| US20090258376A1 (en) | Protein isoforms and uses thereof | |
| JP6262727B2 (ja) | アルツハイマー病及び軽度認知障害関連トロポミオシンアイソフォーム | |
| US20250197944A1 (en) | Differential diagnosis method | |
| KR102410544B1 (ko) | 콧물 시료를 이용한 경도 인지 장애의 진단용 바이오마커 조성물 및 이를 이용한 경도 인지 장애의 진단 방법 | |
| JP6315832B2 (ja) | 非特異的間質性肺炎の診断のためのバイオマーカー | |
| US10317401B2 (en) | Methods and compositions for the prediction and treatment of focal segmental glomerulosclerosis | |
| US20230144446A1 (en) | Blood-based diagnostic assays for alzheimer's disease | |
| US20260072040A1 (en) | Method for measuring cell free chromatin | |
| HK40110041A (zh) | 用於阿尔茨海默病的基於血液的诊断测定 | |
| Hentschel et al. | Protein signature of human white blood cells enables biochemical tracking of rare neurological diseases | |
| Na et al. | Improvement of Clinical Diagnosis Accuracy of Alzheimer’s Disease Using Multiple Blood Biomarkers | |
| WO2023164414A2 (en) | Methods and compositions for evaluating biomarkers in salivary exosomes and evaluating cognitive fatigue |